Page 152 - Read Online

Page 8 of 10 Banini et al. Hepatoma Res 2019;5:34 I http://dx.doi.org/10.20517/2394-5079.2019.30

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2019.

REFERENCES
1. Banini BA, Roberts LR. Hepatocellular carcinoma. Complications of Cirrhosis: Evaluation and management. Springer International
Publishing; 2015. pp. 1-370.
2. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States
from 1975 to 2005. J Clin Oncol 2009;27:1485-91.
3. Punnoose EA, Atwal SK, Spoerke JM, Savage H, Pandita A, et al. Molecular biomarker analyses using circulating tumor cells. PLoS
One 2010;5:e12517.
4. Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol
2013;10:472-84.
5. Hirai H, Taketa K. Lectin affinity electrophoresis of alpha-fetoprotein. Increased specificity and sensitivity as a marker of
hepatocellular carcinoma. J Chromatogr 1992;604:91-4.
6. Bruix J, Sherman M, American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology
2011;53:1020-2.
7. Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound
alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009;137:110-8.
8. Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers
for the early detection of hepatocellular carcinoma. Gastroenterology 2010;138:493-502.
9. Farinati F, Marino D, De Giorgio M, Baldan A, Cantarini M, et al. Diagnostic and prognostic role of alpha-fetoprotein in
hepatocellular carcinoma: both or neither? Am J Gastroenterol 2006;101:524-32.
10. Mandel P, Metais P. Les acides nucléiques du plasma sanguin chez l’homme. C R Seances Soc Biol Fil 1948;142:241-3.
11. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res
1977;37:646-50.
12. Vasioukhin V, Anker P, Maurice P, Lyautey J, Lederrey C, et al. Point mutations of the N-ras gene in the blood plasma DNA of patients
with myelodysplastic syndrome or acute myelogenous leukaemia. Br J Haematol 1994;86:774-9.
13. Cachia PG, Taylor C, Thompson PW, Tennant GB, Masters G, et al. Non-dysplastic myelodysplasia? Leukemia 1994;8:677-81.
14. Sorenson GD, Pribish DM, Valone FH, Memoli VA, Bzik DJ, et al. Soluble normal and mutated DNA sequences from single-copy
genes in human blood. Cancer Epidemiol Biomarkers Prev 1994;3:67-71.
15. Matsumura M, Shiratori Y, Niwa Y, Tanaka T, Ogura K, et al. Presence of alpha-fetoprotein mRNA in blood correlates with outcome
in patients with hepatocellular carcinoma. J Hepatol 1999;31:332-9.
16. Cillo U, Navaglia F, Vitale A, Molari A, Basso D, et al. Clinical significance of alpha-fetoprotein mRNA in blood of patients with
hepatocellular carcinoma. Clin Chim Acta 2004;347:129-38.
17. Jeng KS, Sheen IS, Tsai YC. Does the presence of circulating hepatocellular carcinoma cells indicate a risk of recurrence after
resection? Am J Gastroenterol 2004;99:1503-9.
18. Xu H, Dong X, Chen Y, Wang X. Serum exosomal hnRNPH1 mRNA as a novel marker for hepatocellular carcinoma. Clin Chem Lab
Med 2018;56:479-84.
19. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, et al. Circulating microRNAs as stable blood-based markers for cancer
detection. Proc Natl Acad Sci U S A 2008;105:10513-8.
20. Zheng Q, Zhao J, Yu H, Zong H, He X, et al. Tumor-specific transcripts are frequently expressed in hepatocellular carcinoma with
clinical implication and potential function. Hepatology 2019; doi: 10.1002/hep.30805.
21. Koduru SV, Leberfinger AN, Kawasawa YI, Mahajan M, Gusani NJ, et al. Non-coding RNAs in various stages of liver disease
leading to hepatocellular carcinoma: differential expression of miRNAs, piRNAs, lncRNAs, circRNAs, and sno/mt-RNAs. Sci Rep
2018;8:7967.
22. Tian XP, Wang CY, Jin XH, Li M, Wang FW, et al. Acidic microenvironment up-regulates exosomal miR-21 and miR-10b in early-
stage hepatocellular carcinoma to promote cancer cell proliferation and metastasis. Theranostics 2019;9:1965-79.
23. Koberle V, Kronenberger B, Pleli T, Trojan J, Imelmann E, et al. Serum microRNA-1 and microRNA-122 are prognostic markers in
patients with hepatocellular carcinoma. Eur J Cancer 2013;49:3442-9.
24. Qu KZ, Zhang K, Li H, Afdhal NH, Albitar M. Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin
Gastroenterol 2011;45:355-60.